Jack Anders Sells 2,635 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 2,635 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $45.40, for a total transaction of $119,629.00. Following the completion of the sale, the chief financial officer now directly owns 96,470 shares of the company’s stock, valued at $4,379,738. This represents a 2.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Jack Anders also recently made the following trade(s):

• On Friday, October 11th, Jack Anders sold 10,000 shares of Revolution Medicines stock. The shares were sold at an average price of $50.30, for a total value of $503,000.00.

Revolution Medicines Price Performance

RVMD opened at $42.97 on Thursday. Revolution Medicines, Inc. has a 12 month low of $25.60 and a 12 month high of $62.40. The business has a 50-day moving average of $52.10 and a two-hundred day moving average of $46.03. The stock has a market capitalization of $7.23 billion, a price-to-earnings ratio of -11.97 and a beta of 1.40.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.05). During the same quarter in the prior year, the firm earned ($0.99) earnings per share. Equities research analysts anticipate that Revolution Medicines, Inc. will post -3.5 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Lord Abbett & CO. LLC acquired a new stake in shares of Revolution Medicines in the 3rd quarter worth approximately $83,082,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Revolution Medicines during the 3rd quarter worth $801,000. Geode Capital Management LLC raised its position in shares of Revolution Medicines by 8.7% during the third quarter. Geode Capital Management LLC now owns 3,627,025 shares of the company’s stock worth $164,517,000 after purchasing an additional 291,369 shares during the period. Barclays PLC boosted its position in shares of Revolution Medicines by 187.1% in the 3rd quarter. Barclays PLC now owns 294,664 shares of the company’s stock valued at $13,362,000 after purchasing an additional 192,021 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Revolution Medicines in the third quarter worth about $247,000. Institutional investors own 94.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Oppenheimer lifted their target price on Revolution Medicines from $55.00 to $60.00 and gave the company an “outperform” rating in a report on Monday, October 28th. Piper Sandler lifted their price target on shares of Revolution Medicines from $57.00 to $70.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Wedbush reiterated an “outperform” rating and set a $70.00 target price on shares of Revolution Medicines in a research note on Monday, December 2nd. JPMorgan Chase & Co. raised their price objective on shares of Revolution Medicines from $63.00 to $71.00 and gave the stock an “overweight” rating in a report on Tuesday, December 3rd. Finally, HC Wainwright increased their target price on shares of Revolution Medicines from $64.00 to $72.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Eleven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Revolution Medicines has a consensus rating of “Buy” and an average target price of $63.67.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.